Telma H is manufactured by Glenmark Pharmaceuticals and is prescribed for controlling high blood pressure, particularly in individuals prone to water retention or heart failure

Glenmark Pharmaceuticals Ltd. has gained 29.96% in the last 1 Year

Glenmark Pharmaceuticals Ltd.

28 Mar 2025

1356.80

-1.46%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And …

BSE India

Disclosure under Regulation 30 of SEBI LODR Regulations, 2015

pdf

Glenmark Pharmaceuticals Ltd.

27 Mar 2025

1356.80

-1.46%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Advertisement of Postal Ballot Notice

pdf

Glenmark Pharmaceuticals Ltd.

26 Mar 2025

1356.80

-1.46%

AGM

Glenmark Pharmaceuticals Ltd - 532296 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

BSE India

Intimation regarding Postal Ballot Notice

pdf

Glenmark Pharmaceuticals Ltd.

21 Mar 2025

1356.80

-1.46%

Glenmark Pharma share rises 2% on securing USFDA nod; key details here

Business Standard

Glenmark Pharma's stock rose after it said Glenmark Pharmaceuticals Inc., USA, has received final approval from the USFDA for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%

Glenmark Pharmaceuticals Ltd. has lost -24.83% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

20 Mar 2025

1356.80

-1.46%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%

pdf

Glenmark Pharmaceuticals Ltd.

12 Mar 2025

1356.80

-1.46%

Glenmark launches Empagliflozin for diabetes in India under Glempa brand

Business Standard

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..